US8076515 — Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Method of Use · Assigned to Newron Pharmaceuticals SpA · Expires 2028-12-10 · 3y remaining
What this patent protects
This patent protects a process for producing a specific type of therapeutic compound with high purity, specifically 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides.
USPTO Abstract
A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1993 |
— | safinamide-mesylate |
U-1993 |
— | safinamide-mesylate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.